Dr. Stephen (Steven) Klein

speaker

467 appearances 1 recordings 1 series first heard Jul 2026 last heard 2 Jul

Dr. Stephen (Steven) Klein’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

RECOVERable: Mental Health and Addiction Experts Answer Your Questions · Ozempic and Cravings: How GLP-1 Drugs Work for Addiction · 2 Jul 2026 podcast

And maybe they'll recommend something else first, but eventually getting there.

I think optimistically, my hope is for the next 12 months.

There are some big studies coming through the pipeline.

There are some companies that have brought new versions of GLP-1s that are currently being tested that are going to be just for alcohol use or opioid use disorder.

So there's a lot of movement.

For example, Eli Lilly is the company that makes Monjorno and Zepbound.

They just hired one of the most prominent addiction medicine researchers from the NIH into their company.

So I think there's real attention here.

I think there's really a loud signal.

I'm a member of ASAM, the American Society of Addiction Medicine.

This was a whole topic at our annual meeting last year.

It's a buzz.

It's something that people are talking about.

I think we're getting closer and closer.

We still need those big randomized control trials, which are the real gold standard of demonstrating medical efficacy.

Yeah, the truth is they won't.

They'll all be cross-effective.

What I mean by that statement is, so when we talk about these medications, we're really talking about a molecule.

So think about a ball of spaghetti with a couple of meatballs attached to it.

Those are peptides.

Showing 401–420 of 467 · page 21 of 24